Formycon

Executive Summary

Formycon AG is a German biosimilar developer focused on expanding access to affordable biologic therapies. The company leverages its proprietary platform to develop high-quality biosimilars in ophthalmology, immunology, and oncology. With a robust pipeline including FYB201 (ranibizumab biosimilar) and FYB203 (aflibercept biosimilar), Formycon is well-positioned to capture market share in the growing biosimilar sector. The company's strategy emphasizes cost-efficient development and strategic partnerships, such as its collaboration with Bioeq for FYB201 commercialization in Europe. Formycon's strong regulatory expertise and track record of successful submissions underpin its potential to drive revenue growth and margin expansion as its products gain approvals.

Upcoming Catalysts (preview)

• Q3 2026FYB203 (aflibercept biosimilar) Phase 3 top-line results85% success
• Q4 2026FYB201 (ranibizumab biosimilar) EMA approval decision80% success
• Q2 2026Partnering deal for FYB206 (biosimilar of Prolia/Evenity) or other pipeline asset60% success